Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 46 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
Purpose: To provide examples of other conditions that are improved following treatment with dextroamphetamine sulfate that would not involve hyperalgesia and/or edema. Thus elucidation of such conditions would demonstrate the need to change the name from the sympathetic neural hyperalgesia syndrome to a name that would cover all conditions responding to sympathomimetic amine therapy. Materials and Methods: Cases of chronic fatigue syndrome and various skin and neurologic disorders and temperature regulation conditions are provided as examples of conditions responding well to dextroamphetamine sulfate that do not involve either pain or edema. Results: Examples are provided that show that inherited permeability defects in certain tissues or inherited sympathetic nervous system hypofunction produce symptoms other than pain or swelling yet respond to dextroamphetamine sulfate. Conclusions: Though lacking "pizzazz", the new name given to this condition refers to the main hypothesized defect whether inherited or acquired, and that is increased cellular permeability. Thus, the new name is the increased cellular permeability syndrome in lieu of the sympathetic neural hyperalgesia – edema syndrome which had replaced the name idiopathic edema.